1386398-53-3

Basic information

• Product Name: N-{3-[6-(2-amino-1-phenyl-ethylamino)-pyridin-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-cyclohexane-1,4-diamine hydrochloride
• Synonyms: N-{3-[6-(2-amino-1-phenyl-ethylamino)-pyridin-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-cyclohexane-1,4-diamine hydrochloride
• CAS NO: 1386398-53-3
• Molecular Weight: 480.015
• Mol File: 1386398-53-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-{3-[6-(2-amino-1-phenyl-ethylamino)-pyridin-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-cyclohexane-1,4-diamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[6-(2-amino-1-phenyl-ethylamino)-pyridin-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-cyclohexane-1,4-diamine hydrochloride(1386398-53-3)
• EPA Substance Registry System: N-{3-[6-(2-amino-1-phenyl-ethylamino)-pyridin-2-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}-cyclohexane-1,4-diamine hydrochloride(1386398-53-3)

Safety Data

• Hazardous Substances Data: 1386398-53-3(Hazardous Substances Data)

Upstream product

• 67341-07-5 tert-butyl N-(2-hydroxy-2-phenylethyl)carbamate 
• 34160-40-2 6-bromo-2-pyridinecarbaldehyde 
• 7568-93-6 2-Amino-1-phenylethanol 
• 943321-52-6 tert-butyl 2-(1,3-dioxoisoindolin-2-yl)-2-phenylethylcarbamate 
• 1386399-12-7 {4-[3-(6-bromo-pyridin-2-yl)-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino]-cyclohexyl}-carbamic acid tert-butyl ester 
• 174885-99-5 (±)-tert-butyl N-(2-amino-2-phenylethyl)carbamate 
• 1386399-06-9 3-(6-bromo-pyridin-2-yl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 1386399-04-7 (6-bromo-pyridin-2-yl)-(2,4-dichloro-pyrimidin-5-yl)-methanol 
• 1386399-05-8 (6-bromo-pyridin-2-yl)-(2,4-dichloro-pyrimidin-5-yl)-methanone 
• 1386399-11-6 3-(6-bromo-pyridin-2-yl)-6-chloro-1-trityl-1H-pyrazolo[3,4-d]pyrimidine 
• 1386399-47-8 (4-{3-[6-(2-tert-butoxycarbonylamino-1-phenyl-ethylamino)-pyridin-2-yl]-1-trityl-1H-pyrazolo[3,4-d]pyrimidin-6-ylamino}-cyclohexyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.